Skip to main content
OpenTrials
Completed

NCT Number: NCT06122038

Impact of Powdered Tart Cherries on Recovery From Repeated Sprints

The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Exercise and Performance Nutrition Laboratory

Saint Charles, Missouri, 63301, United States

About this study

The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females. This study will utilize a randomized, double-blind, placebo group study design. Prior to any data collection, potential participants will be explained the protocol and then review and sign an IRB-approved consent form. Healthy male and female (n=40) participants who report regularly practicing or competing in high-intensity multi-modal resistance based exercise will complete the study protocol.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male and female (n=40) participants between the ages of 18 - 35 years of age will finish the study protocol. An even distribution of males (n=20) and females (n=20) is planned.
  • Participating in some form of exercise at least four days per week with at least two days consisting of some form of high-intensity exercise for the past six months.
  • Examples include regular gym attendance to complete resistance training, interval exercise, or participation in some form of organized physical activity involving high-speed running or other forms of high-intensity exercise.
  • Have a body mass index (BMI) range of 18.0 - 30.0 kg/m2. Males with a body mass index greater than 30.0 kg/m2, but a body fat percentage less than 27.5% fat will be accepted into the study. Females with a body mass index greater than 30.0 kg/m2, but a body fat percentage less than 32.5% fat will be accepted into the study.

Exclusion criteria

  • Participant has a positive medical history of heart disease/cardiovascular disease, uncontrolled hypertension (140/90 or greater mmHg), kidney disease (dialysis or renal failure), hepatic impairment or disease, or Type I or Type II diabetes.
  • Participant has a positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorder (i.e., HIV/AIDS), a history of cancer (except localized skin cancer without metastases or in situ cervical cancer within five years prior to screening visit.
  • Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g. dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)
  • Positive medical history for any neurological condition or neurological disease
  • Currently smoke or have quit within the past six months
  • Current daily use of aspirin, NSAIDS, naproxen sodium, COX-2 inhibitors, or any other over-the-counter or prescribed medication indicated for pain relief.
  • Intake of any dietary supplement known or purported to impact muscle repair and recovery such as antioxidants, curcumin, turmeric, branched-chain amino acids, vitamin D, tart cherry, pomegranate, fish oils, or creatine monohydrate.
  • Individuals who indicate they are actively involved in any form of a dietary program in the past 30 days to lose weight
  • Participants who are lactating, pregnant or planning to become pregnant
  • Have a known sensitivity or allergy to any of the study products
  • Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data
  • History of alcohol or substance abuse in the 12 months prior to screening
  • Receipt or use of an investigational product in another research study within 28 days prior to baseline testing

Treatment and study plan

Tart Cherry Extract Powder

Dietary Supplement

Tart Cherry Extract Powder (ADSO Naturals). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.

Placebo

Dietary Supplement

Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.

Primary outcomes

  1. Counter movement Jump Height

    Time frame: 10 days

    Jump height from counter movement jump

  2. Counter movement jump peak propulsive force (N)

    Time frame: 10 days

    Peak propulsive force (N) from counter movement jump

  3. Counter movement jump relative breaking force (N)

    Time frame: 10 days

    relative breaking force (N/kg) from counter movement jump

  4. Isokinetic knee extension maximal voluntary contraction.

    Time frame: 10 days

    Peak isokinetic knee extension force (N) from a isokinetic knee extension exercise using a Biodex System 3

  5. Isometric mid-thigh pull maximal voluntary contraction

    Time frame: 10 days

    Isometric maximal voluntary contraction peak force will be measured using an isometric mid-thigh pull assessment. Peak force production will be measured in Newtons.

  6. Perceived recovery Visual Analog Scale

    Time frame: 10 days

    Perceived recovery Visual Analog Scale ranging from 0 (worst) to 100 (best)

  7. Perceived soreness Visual Analog Scale

    Time frame: 10 days

    Perceived soreness Visual Analog Scale ranging from 0 (worst) to 100 (best)

  8. Pain to Pressure threshold

    Time frame: 10 days

    Pain to Pressure threshold from algometry (higher = less sore). Minimum values are 0 N, maximum values are 110 N

  9. Changes in Creatine Kinase concentrations

    Time frame: 10 days

    Changes in Creatine kinase concentrations following damaging exercise

  10. Changes in Creatine Kinase-myocardial band concentrations

    Time frame: 10 days

    Changes in Creatine kinase-myocardial band concentrations following damaging exercise

  11. Sprint time

    Time frame: Baseline

    Fastest and average sprint time during 15 30-meter sprint recorded using digitally timed timing gates

Secondary outcomes

  1. Peak power

    Time frame: 10 days

    Peak power during a wingate anaerobic test

  2. Changes in Protein carbonyls concentration

    Time frame: 10 days

    Protein carbonyls concentration changes

  3. Changes in 8-isoprostane concentration

    Time frame: 10 days

    8-isoprostane concentration changes

  4. Changes in testosterone-cortisol ratio

    Time frame: 10 days

    Testosterone-cortisol ratio changes

  5. Changes in TNF-alpha concentration

    Time frame: 10 days

    Changes in TNF-alpha concentration

  6. Changes in IL-6 concentration

    Time frame: 10 days

    Changes in IL-6 concentration

  7. Changes in IL-10 concentration

    Time frame: 10 days

    Changes in IL-10 concentration

  8. Desire to exercise visual analog scale

    Time frame: 10 days

    Desire to exercise visual analog scale (0 = not ready to train, 100 = very ready to train)

  9. Pittsburgh sleepiness Scale Score

    Time frame: 10 days

    Pittsburgh sleepiness Scale Score (lower scores indicate higher level of sleepiness)

  10. Changes in Uric Acid Concentrations

    Time frame: 10 days

    Changes in Uric Acid concentrations

Other outcomes

  1. Resting Heart Rate

    Time frame: 10 days

    Resting heart rate at all study visits

  2. Resting Blood pressure

    Time frame: 10 days

    Resting Blood pressure at all study visits

  3. Reported Adverse Events

    Time frame: 10 days

    Self-Reported Adverse Events

Sponsors and collaborators

Lead sponsor

Lindenwood University

Other

Registry information

Official study title

Impact of Powdered Tart Cherries on Recovery From Repeated Sprints in Trained Males and Females

Acronym: TCR

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Nov 8, 2023
Registry last updated
Jan 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.